Biogen and Eisai expand Alzheimer's collaboration

23 October 2017
2019_biotech_test_vial_discovery_big

Japanese and US pharma majors Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) say they have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments.

Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (AD). Perhaps surprisingly, shares of Biogen dipped 2.35% to$330.20 by mid-morning trading today.

Phase III data for aducanumab is expected in late 2019 or early 2020. This "could be one of the first disease-modifying drugs to reach the market," Goldman Sachs analyst Terence Flynn wrote in a note to clients back in the summer. Mr Flynn envisages peak sales of $12 billion for aducanumab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology